2025年1月2日 · The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t materialized, and most companies that did reach Wall Street in 2024 struggled to hold their value.

BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.

2024年11月21日 · Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if ever. So more often than not, a startup’s success turning science into medicines can come down to how much money it raises.

2025年1月2日 · The Dec. 20 clearance of Alyftrek came a few weeks ahead of the agency’s Jan. 2 decision deadline, and extends Vertex’s dominance in the lung disease cystic fibrosis. Prior to Alyftrek’s approval, Vertex had previously brought four cystic fibrosis medicines to market, building a business that generated nearly $10 billion in 2023.

What to expect at JPM 2025. 1. Innovative therapies and technologies: Expect spotlight sessions on the latest in gene editing, AI-driven diagnostics and novel drug delivery systems. While many presentation topics are not disclosed prior to the event, one anticipated highlight is from Anavex Life Sciences Corp (NASDAQ: AVXL), who is set to present Phase 2/3 data of blarcamesine (ANAVEX2-73-AD ...

2024年11月22日 · Notably, the drug is approved to prevent hospitalization or death resulting from heart complications of transthyretin amyloidosis with cardiomyopathy. Investors had been skeptical BridgeBio would earn such a distinction from regulators, leading to doubts about Attruby’s commercial prospects.. BridgeBio priced Attruby at just under $19,000 for a 28-day supply, translating to an annual list ...

2024年9月23日 · A guidance from the U.S. FDA (draft updated in March 2020) requires data on cardiovascular events in new T2D drug development programs.As a result, dedicated cardiovascular safety trials were implemented. Many demonstrated beneficial effects of GLP-1 RAs on the heart and kidneys in patients with T2D (with and without preexisting conditions), with those effects thought to be largely independent ...

2023年9月15日 · “Our updated brand identity communicates our bold approach to innovation in healthcare while staying true to the care we share to patients, doctors, nurses and those who use our products,” Tesia Williams, a senior director of corporate media relations at J&J, wrote in …

2024年10月1日 · American Association of Cancer Research Annual Meeting. April 25 - 30, 2025 Chicago. While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer research, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.

2024年5月8日 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.